

Vittorio Rosti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9189779/publications.pdf>

Version: 2024-02-01

211
papers

9,039
citations

34016

52
h-index

48187

88
g-index

216
all docs

216
docs citations

216
times ranked

9382
citing authors

#	ARTICLE	IF	CITATIONS
1	Conjugated polymers mediate intracellular Ca ²⁺ signals in circulating endothelial colony forming cells through the reactive oxygen species-dependent activation of Transient Receptor Potential Vanilloid 1 (TRPV1). <i>Cell Calcium</i> , 2022, 101, 102502.	1.1	19
2	Reduced CXCR4-expression on CD34-positive blood cells predicts outcomes of persons with primary myelofibrosis. <i>Leukemia</i> , 2021, 35, 468-475.	3.3	7
3	Nicotinic acid adenine dinucleotide phosphate activates two-pore channel TPC1 to mediate lysosomal Ca ²⁺ release in endothelial colony-forming cells. <i>Journal of Cellular Physiology</i> , 2021, 236, 688-705.	2.0	22
4	Cytogenetic study in primary myelofibrosis at diagnosis: Clinical and histological association and impact on survival according to WHO 2017 classification in an Italian multicenter series. <i>Hematological Oncology</i> , 2021, 39, 123-128.	0.8	1
5	Increased B4GALT1 expression is associated with platelet surface galactosylation and thrombopoietin plasma levels in MPNs. <i>Blood</i> , 2021, 137, 2085-2089.	0.6	11
6	Co-mutation pattern, clonal hierarchy, and clone size concur to determine disease phenotype of SRSF2P95-mutated neoplasms. <i>Leukemia</i> , 2021, 35, 2371-2381.	3.3	17
7	Gene expression profile correlates with molecular and clinical features in patients with myelofibrosis. <i>Blood Advances</i> , 2021, 5, 1452-1462.	2.5	8
8	Impact of the rs1024611 Polymorphism of CCL2 on the Pathophysiology and Outcome of Primary Myelofibrosis. <i>Cancers</i> , 2021, 13, 2552.	1.7	9
9	The human amniotic fluid stem cell secretome triggers intracellular Ca ²⁺ oscillations, NF- κ B nuclear translocation and tube formation in human endothelial colony-forming cells. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 8074-8086.	1.6	18
10	Clinical Relevance of VEGFA (rs3025039) +936 C>T Polymorphism in Primary Myelofibrosis: Susceptibility, Clinical Co-Variates, and Outcomes. <i>Genes</i> , 2021, 12, 1271.	1.0	4
11	Increased Plasma Levels of lncRNAs LINC01268, GAS5 and MALAT1 Correlate with Negative Prognostic Factors in Myelofibrosis. <i>Cancers</i> , 2021, 13, 4744.	1.7	9
12	New Markers of Disease Progression in Myelofibrosis. <i>Cancers</i> , 2021, 13, 5324.	1.7	6
13	Primary myelofibrosis: rs2010963 VEGFA polymorphism favors a prefibrotic phenotype and is associated with higher risk of thrombosis. <i>Leukemia Research</i> , 2021, 111, 106730.	0.4	3
14	VEGFA rs3025020 Polymorphism Contributes to CALR-Mutation Susceptibility and Is Associated with Low Risk of Deep Vein Thrombosis in Primary Myelofibrosis. <i>TH Open</i> , 2021, 05, e513-e520.	0.7	1
15	Therapeutic Potential of Endothelial Colony-Forming Cells in Ischemic Disease: Strategies to Improve their Regenerative Efficacy. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7406.	1.8	30
16	Endothelial TRPV1 as an Emerging Molecular Target to Promote Therapeutic Angiogenesis. <i>Cells</i> , 2020, 9, 1341.	1.8	36
17	Systemic lupus erythematosus, endothelial progenitor cells and intracellular Ca ²⁺ signaling: A novel approach for an old disease. <i>Journal of Autoimmunity</i> , 2020, 112, 102486.	3.0	10
18	Plasma sIL-2R β levels are associated with disease progression in myelofibrosis with JAK2V617F but not CALR mutation. <i>Leukemia Research</i> , 2020, 90, 106319.	0.4	7

#	ARTICLE	IF	CITATIONS
19	Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study. <i>Lancet Haematology</i> , 2020, 7, e226-e237.	2.2	93
20	Defective interaction of mutant calreticulin and SOCE in megakaryocytes from patients with myeloproliferative neoplasms. <i>Blood</i> , 2020, 135, 133-144.	0.6	52
21	Supporting data on in vitro cardioprotective and proliferative paracrine effects by the human amniotic fluid stem cell secretome. <i>Data in Brief</i> , 2019, 25, 104324.	0.5	14
22	Constitutive STAT5 phosphorylation in CD34+ cells of patients with primary myelofibrosis: Correlation with driver mutation status and disease severity. <i>PLoS ONE</i> , 2019, 14, e0220189.	1.1	3
23	Generation of donor-derived Wilms tumor antigen specific cytotoxic T lymphocytes with potent anti-leukemia activity for somatic cell therapy in children given haploidentical stem cell transplantation: a feasibility pre-clinical study. <i>Cytotherapy</i> , 2019, 21, 958-972.	0.3	4
24	A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis. <i>Leukemia</i> , 2019, 33, 2974-2978.	3.3	19
25	A novel disorder involving dyshematopoiesis, inflammation, and HLH due to aberrant CDC42 function. <i>Journal of Experimental Medicine</i> , 2019, 216, 2778-2799.	4.2	132
26	Conjugated polymers optically regulate the fate of endothelial colony-forming cells. <i>Science Advances</i> , 2019, 5, eaav4620.	4.7	61
27	Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea. <i>Blood</i> , 2019, 134, 1498-1509.	0.6	123
28	Reactivating endogenous mechanisms of cardiac regeneration via paracrine boosting using the human amniotic fluid stem cell secretome. <i>International Journal of Cardiology</i> , 2019, 287, 87-95.	0.8	57
29	EDA fibronectin-TLR4 axis sustains megakaryocyte expansion and inflammation in bone marrow fibrosis. <i>Journal of Experimental Medicine</i> , 2019, 216, 587-604.	4.2	36
30	Kinetic and Angiogenic Activity of Circulating Endothelial Colony Forming Cells in Patients with Infantile Haemangioma Receiving Propranolol. <i>Thrombosis and Haemostasis</i> , 2019, 119, 274-284.	1.8	7
31	Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts. <i>Leukemia</i> , 2018, 32, 1200-1210.	3.3	101
32	The spleen of patients with myelofibrosis harbors defective mesenchymal stromal cells. <i>American Journal of Hematology</i> , 2018, 93, 615-622.	2.0	8
33	Involvement of MAF/SPP1 axis in the development of bone marrow fibrosis in PMF patients. <i>Leukemia</i> , 2018, 32, 438-449.	3.3	26
34	Stromal Cell-Derived Factor-1 Promotes Endothelial Colony-Forming Cell Migration Through the Ca ²⁺ -Dependent Activation of the Extracellular Signal-Regulated Kinase 1/2 and Phosphoinositide 3-Kinase/AKT Pathways. <i>Stem Cells and Development</i> , 2018, 27, 23-34.	1.1	41
35	MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis. <i>Journal of Clinical Oncology</i> , 2018, 36, 310-318.	0.8	373
36	Role of TGF- β 1/miR-382-5p/ SOD 2 axis in the induction of oxidative stress in CD 34+ cells from primary myelofibrosis. <i>Molecular Oncology</i> , 2018, 12, 2102-2123.	2.1	19

#	ARTICLE	IF	CITATIONS
37	The role of endothelial colony forming cells in kidney cancer's pathogenesis, and in resistance to anti-VEGFR agents and mTOR inhibitors: A speculative review. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 132, 89-99.	2.0	24
38	Long-Term Efficacy and Safety (5 Years) in RESPONSE, a Phase 3 Study Comparing Ruxolitinib (rux) with Best Available Therapy (BAT) in Hydroxyurea (HU)-Resistant/Intolerant Patients (pts) with Polycythemia Vera (PV). <i>Blood</i> , 2018, 132, 1753-1753.	0.6	7
39	Abnormal Regulation of Intracellular Calcium in Human Megakaryocytes Contributes to the Pathophysiology of Calr-Mutant Myeloproliferative Neoplasms. <i>Blood</i> , 2018, 132, 1782-1782.	0.6	1
40	Manipulating Intracellular Ca ²⁺ Signals to Stimulate Therapeutic Angiogenesis in Cardiovascular Disorders. <i>Current Pharmaceutical Biotechnology</i> , 2018, 19, 686-699.	0.9	19
41	Increased STAT5/STAT3 Intracellular Signaling in Circulating CD34+ Cells of Patients with PMF Correlates with Disease Severity. <i>Blood</i> , 2018, 132, 4337-4337.	0.6	0
42	Antitumour activity of trabectedin in myelodysplastic/myeloproliferative neoplasms. <i>British Journal of Cancer</i> , 2017, 116, 335-343.	2.9	20
43	Breast and renal cancer-Derived endothelial colony forming cells share a common gene signature. <i>European Journal of Cancer</i> , 2017, 77, 155-164.	1.3	19
44	Vascular endothelial growth factor overexpression in myelodysplastic syndrome bone marrow cells: biological and clinical implications. <i>Leukemia and Lymphoma</i> , 2017, 58, 1711-1720.	0.6	3
45	Acetylcholine induces intracellular Ca ²⁺ oscillations and nitric oxide release in mouse brain endothelial cells. <i>Cell Calcium</i> , 2017, 66, 33-47.	1.1	65
46	Primary myelofibrosis: Older age and high JAK2V617F allele burden are associated with elevated plasma high-sensitivity C-reactive protein levels and a phenotype of progressive disease. <i>Leukemia Research</i> , 2017, 60, 18-23.	0.4	27
47	Liposomes as a Putative Tool to Investigate NAADP Signaling in Vasculogenesis. <i>Journal of Cellular Biochemistry</i> , 2017, 118, 3722-3729.	1.2	25
48	Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis. <i>Blood</i> , 2017, 129, 3227-3236.	0.6	137
49	Endothelial-to-Mesenchymal Transition in Bone Marrow and Spleen of Primary Myelofibrosis. <i>American Journal of Pathology</i> , 2017, 187, 1879-1892.	1.9	17
50	Upregulation of lysyl oxidase and adhesion to collagen of human megakaryocytes and platelets in primary myelofibrosis. <i>Blood</i> , 2017, 130, 829-831.	0.6	30
51	Parental origin of the deletion del(20q) in Shwachman-Diamond patients and loss of the paternally derived allele of the imprinted <i>L3MBTL1</i> gene. <i>Genes Chromosomes and Cancer</i> , 2017, 56, 51-58.	1.5	12
52	Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasms. <i>American Journal of Hematology</i> , 2017, 92, 187-195.	2.0	41
53	VEGF-induced intracellular Ca ²⁺ oscillations are down-regulated and do not stimulate angiogenesis in breast cancer-derived endothelial colony forming cells. <i>Oncotarget</i> , 2017, 8, 95223-95246.	0.8	41
54	miR-494-3p overexpression promotes megakaryocytopoiesis in primary myelofibrosis hematopoietic stem/progenitor cells by targeting SOCS6. <i>Oncotarget</i> , 2017, 8, 21380-21397.	0.8	13

#	ARTICLE	IF	CITATIONS
55	Fine structural detection of calcium ions by photoconversion. <i>European Journal of Histochemistry</i> , 2016, 60, 2695.	0.6	7
56	Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients. <i>American Journal of Hematology</i> , 2016, 91, 918-922.	2.0	47
57	Endoplasmic Reticulum Ca ²⁺ Handling and Apoptotic Resistance in Tumor-Derived Endothelial Colony Forming Cells. <i>Journal of Cellular Biochemistry</i> , 2016, 117, 2260-2271.	1.2	24
58	Thrombopoietin/TGF- β 1 Loop Regulates Megakaryocyte Extracellular Matrix Component Synthesis. <i>Stem Cells</i> , 2016, 34, 1123-1133.	1.4	49
59	Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial. <i>Haematologica</i> , 2016, 101, 821-829.	1.7	140
60	Constitutive Store-Operated Ca ²⁺ Entry Leads to Enhanced Nitric Oxide Production and Proliferation in Infantile Hemangioma-Derived Endothelial Colony-Forming Cells. <i>Stem Cells and Development</i> , 2016, 25, 301-319.	1.1	51
61	Reduced frequency of circulating CD4 ⁺ CD25 ^{bright} CD127 ^{low} FOXP3 ⁺ regulatory T cells in primary myelofibrosis. <i>Blood</i> , 2016, 128, 1660-1662.	0.6	13
62	Arachidonic acid-evoked Ca ²⁺ signals promote nitric oxide release and proliferation in human endothelial colony forming cells. <i>Vascular Pharmacology</i> , 2016, 87, 159-171.	1.0	51
63	Increased plasma nicotinamide phosphoribosyltransferase is associated with a hyperproliferative phenotype and restrains disease progression in MPN-associated myelofibrosis. <i>American Journal of Hematology</i> , 2016, 91, 709-713.	2.0	6
64	Integrative analysis of copy number and gene expression data suggests novel pathogenetic mechanisms in primary myelofibrosis. <i>International Journal of Cancer</i> , 2016, 138, 1657-1669.	2.3	6
65	Altered fibronectin expression and deposition by myeloproliferative neoplasm-derived mesenchymal stromal cells. <i>British Journal of Haematology</i> , 2016, 172, 140-144.	1.2	18
66	JAK2V617F allele burden \geq 450% is associated with response to ruxolitinib in persons with MPN-associated myelofibrosis and splenomegaly requiring therapy. <i>Leukemia</i> , 2016, 30, 1772-1775.	3.3	50
67	Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms. <i>Leukemia</i> , 2016, 30, 431-438.	3.3	216
68	High Levels of High Sensitivity-C Reactive Protein (hs-CRP) Are Associated with Older Age, Chromosomal Abnormalities and JAK2V617F Mutation with High Allele Burden in Primary Myelofibrosis (PMF). <i>Blood</i> , 2016, 128, 1956-1956.	0.6	1
69	Tie2 Expressing Monocytes in the Spleen of Patients with Primary Myelofibrosis. <i>PLoS ONE</i> , 2016, 11, e0156990.	1.1	3
70	Targeting Stim and Orai Proteins as an Alternative Approach in Anticancer Therapy. <i>Current Medicinal Chemistry</i> , 2016, 23, 3450-3480.	1.2	55
71	A Newly Identified Platelet and Megakaryocyte Lysyl Oxidase-Adhesion to Collagen Axis in Human Primary Myelofibrosis. <i>Blood</i> , 2016, 128, 3133-3133.	0.6	0
72	MiR-494-3p Overexpression Leads to SOCS6 Downregulation and Supports Megakaryocytopoiesis in Primary Myelofibrosis CD34 ⁺ Hematopoietic Stem/Progenitor Cells. <i>Blood</i> , 2016, 128, 4272-4272.	0.6	0

#	ARTICLE	IF	CITATIONS
73	Deregulated Genes in Hematopoietic Stem Cells Isolated from Spleen of Patients with Myelofibrosis. <i>Blood</i> , 2016, 128, 4279-4279.	0.6	0
74	Differences in Clinical and Molecular Characteristics and Outcome in Prefibrotic and Overt Primary Myelofibrosis According to 2016 WHO Criteria. a Study on 639 Patients of the Agimm Group. <i>Blood</i> , 2016, 128, 943-943.	0.6	1
75	Comprehensive characterization of mesenchymal stromal cells from patients with Fanconi anaemia. <i>British Journal of Haematology</i> , 2015, 170, 826-836.	1.2	23
76	Critical appraisal of the role of ruxolitinib in myeloproliferative neoplasm-associated myelofibrosis. <i>OncoTargets and Therapy</i> , 2015, 8, 1091.	1.0	17
77	Conditioned Medium From Human Amniotic Mesenchymal Stromal Cells Limits Infarct Size and Enhances Angiogenesis. <i>Stem Cells Translational Medicine</i> , 2015, 4, 448-458.	1.6	94
78	Dysregulation of VEGF-induced proangiogenic Ca ²⁺ oscillations in primary myelofibrosis-derived endothelial colony-forming cells. <i>Experimental Hematology</i> , 2015, 43, 1019-1030.e3.	0.2	46
79	Increase of circulating endothelial cells in patients with Hereditary Hemorrhagic Telangiectasia. <i>International Journal of Hematology</i> , 2015, 101, 23-31.	0.7	3
80	Expression and function of toll-like receptors in human circulating endothelial colony forming cells. <i>Immunology Letters</i> , 2015, 168, 98-104.	1.1	6
81	Endothelial progenitor cells support tumour growth and metastatisation: implications for the resistance to anti-angiogenic therapy. <i>Tumor Biology</i> , 2015, 36, 6603-6614.	0.8	66
82	A Functional Transient Receptor Potential Vanilloid 4 (TRPV4) Channel Is Expressed in Human Endothelial Progenitor Cells. <i>Journal of Cellular Physiology</i> , 2015, 230, 95-104.	2.0	45
83	Long Term Follow up of a Phase 2 Study of Ruxolitinib in Patients with Splanchnic Vein Thrombosis Associated with Myeloproliferative Neoplasm. <i>Blood</i> , 2015, 126, 2803-2803.	0.6	2
84	Prognostic Impact of Bone Marrow Fibrosis in Primary Myelofibrosis: A Study of Agimm Group on 540 Patients. <i>Blood</i> , 2015, 126, 351-351.	0.6	1
85	JAK2 Exon 14 Skipping in Patients with Primary Myelofibrosis: A Minor Splice Variant Modulated by the JAK2-V617F Allele Burden. <i>PLoS ONE</i> , 2015, 10, e0116636.	1.1	8
86	Possible Role of Impaired Erk1,2 Phosphorilation and Increased sIL2r Alpha Plasma Levels in the Reduced Frequency of Circulating T Regulatory Cells of Patients with Primary Myelofibrosis. <i>Blood</i> , 2015, 126, 1639-1639.	0.6	0
87	V617FJAK2-Positive Endothelial Cells Are Present in Bone Marrow Neovessels of Patients with Myelofibrosis and Could Derive from the Transdifferentiation of Mutated Hematopoietic Cells. <i>Blood</i> , 2015, 126, 2833-2833.	0.6	0
88	Ca ²⁺ Signalling in Endothelial Progenitor Cells: A Novel Means to Improve Cell-Based Therapy and Impair Tumour Vascularisation. <i>Current Vascular Pharmacology</i> , 2014, 12, 87-105.	0.8	61
89	Rapid and long-lasting decrease of T-regulatory cells in patients with myelofibrosis treated with ruxolitinib. <i>Leukemia</i> , 2014, 28, 449-451.	3.3	63
90	Store-Operated Ca ²⁺ Entry Does Not Control Proliferation in Primary Cultures of Human Metastatic Renal Cellular Carcinoma. <i>BioMed Research International</i> , 2014, 2014, 1-19.	0.9	51

#	ARTICLE	IF	CITATIONS
91	Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. <i>Blood</i> , 2014, 124, 1062-1069.	0.6	340
92	48 Trabectedin and lurbinectedin are effective against leukemic cells derived from patients affected by chronic and juvenile myelomonocytic leukemia. <i>European Journal of Cancer</i> , 2014, 50, 21.	1.3	0
93	Functional and genetic aberrations of in vitro-cultured marrow-derived mesenchymal stromal cells of patients with classical Philadelphia-negative myeloproliferative neoplasms. <i>Leukemia</i> , 2014, 28, 1742-1745.	3.3	30
94	Hydrogen sulphide triggers VEGF-induced intracellular Ca ²⁺ signals in human endothelial cells but not in their immature progenitors. <i>Cell Calcium</i> , 2014, 56, 225-234.	1.1	59
95	CD14 ^{bright} CD16 ^{low} intermediate monocytes expressing Tie2 are increased in the peripheral blood of patients with primary myelofibrosis. <i>Experimental Hematology</i> , 2014, 42, 244-246.	0.2	9
96	miRNA-mRNA integrative analysis in primary myelofibrosis CD34 ⁺ cells: role of miR-155/JARID2 axis in abnormal megakaryopoiesis. <i>Blood</i> , 2014, 124, e21-e32.	0.6	105
97	A Phase 2 Study of Ruxolitinib in Patients with Splanchnic Vein Thrombosis Associated with Myeloproliferative Neoplasm: A Study from the AGIMM Group. <i>Blood</i> , 2014, 124, 3192-3192.	0.6	1
98	Mutation-Enhanced International Prognostic Scoring System (MIPSS) for Primary Myelofibrosis: An AGIMM & IWG-MRT Project. <i>Blood</i> , 2014, 124, 405-405.	0.6	47
99	Enhanced Expression of Stim, Orai, and TRPC Transcripts and Proteins in Endothelial Progenitor Cells Isolated from Patients with Primary Myelofibrosis. <i>PLoS ONE</i> , 2014, 9, e91099.	1.1	60
100	A Subpopulation of Circulating Endothelial Cells Express CD109 and is Enriched in the Blood of Cancer Patients. <i>PLoS ONE</i> , 2014, 9, e114713.	1.1	17
101	Orai1 and Transient Receptor Potential Channels as Novel Molecular Targets to Impair Tumor Neovascularization in Renal Cell Carcinoma and other Malignancies. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2014, 14, 296-312.	0.9	46
102	What Is the True Response Rate to Ruxolitinib in Persons with Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis (MF) Needing Therapy for Splenomegaly?. <i>Blood</i> , 2014, 124, 3191-3191.	0.6	15
103	Phenotypical, Functional and Genetic Characterization of Mesenchymal Stem Cells Derived from the Spleen of Patients with Myelofibrosis. <i>Blood</i> , 2014, 124, 3227-3227.	0.6	0
104	Biological, functional and genetic characterization of bone marrow-derived mesenchymal stromal cells isolated from pediatric patients affected by acute lymphoblastic leukemia. <i>Experimental Hematology</i> , 2013, 41, S56-S57.	0.2	0
105	Remote Ischemic Post-Conditioning of the Lower Limb During Primary Percutaneous Coronary Intervention Safely Reduces Enzymatic Infarct Size in Anterior Myocardial Infarction. <i>JACC: Cardiovascular Interventions</i> , 2013, 6, 1055-1063.	1.1	189
106	How to utilize Ca ²⁺ signals to rejuvenate the reparative phenotype of senescent endothelial progenitor cells in elderly patients affected by cardiovascular diseases: a useful therapeutic support of surgical approach?. <i>BMC Surgery</i> , 2013, 13, S46.	0.6	44
107	Canonical Transient Receptor Potential 3 Channel Triggers Vascular Endothelial Growth Factor-Induced Intracellular Ca ²⁺ Oscillations in Endothelial Progenitor Cells Isolated from Umbilical Cord Blood. <i>Stem Cells and Development</i> , 2013, 22, 2561-2580.	1.1	74
108	Elevated C-reactive protein is associated with shortened leukemia-free survival in patients with myelofibrosis. <i>Leukemia</i> , 2013, 27, 2084-2086.	3.3	51

#	ARTICLE	IF	CITATIONS
109	No association between the XPD Lys751Gln (rs13181) polymorphism and disease phenotype or leukemic transformation in primary myelofibrosis. <i>Haematologica</i> , 2013, 98, e83-e84.	1.7	4
110	Effects of mitochondrial ferritin overexpression in normal and sideroblastic erythroid progenitors. <i>British Journal of Haematology</i> , 2013, 161, 726-737.	1.2	10
111	Spleen endothelial cells from patients with myelofibrosis harbor the JAK2V617F mutation. <i>Blood</i> , 2013, 121, 360-368.	0.6	102
112	Different Subsets of Circulating Angiogenic Cells Do not Predict Bronchopulmonary Dysplasia or other Diseases of Prematurity in Preterm Infants. <i>International Journal of Immunopathology and Pharmacology</i> , 2013, 26, 809-816.	1.0	8
113	Involvement of TGF β 1 in autocrine regulation of proplatelet formation in healthy subjects and patients with primary myelofibrosis. <i>Haematologica</i> , 2013, 98, 514-517.	1.7	29
114	A Phase 2 Study Of Ruxolitinib In Patients With Splanchnic Vein Thrombosis Associated With Myeloproliferative Neoplasm. Preliminary Results. <i>Blood</i> , 2013, 122, 1583-1583.	0.6	4
115	JAK2 V617F Genotype Is a Strong Determinant of Blast Transformation in Primary Myelofibrosis. <i>PLoS ONE</i> , 2013, 8, e59791.	1.1	15
116	Biological, Functional and Genetic Characterization of Bone Marrow-Derived Mesenchymal Stromal Cells from Pediatric Patients Affected by Acute Lymphoblastic Leukemia. <i>PLoS ONE</i> , 2013, 8, e76989.	1.1	29
117	Integrative Analysis Of mRNA/miRNA Expression Profiles Identified JARID2 As a Shared Target Of Deregulated Mirnas In Primary Myelofibrosis. <i>Blood</i> , 2013, 122, 1600-1600.	0.6	0
118	Store-Dependent Ca ²⁺ Entry in Endothelial Progenitor Cells As a Perspective Tool to Enhance Cell-Based Therapy and Adverse Tumour Vascularization. <i>Current Medicinal Chemistry</i> , 2012, 19, 5802-5818.	1.2	108
119	Hematopoietic Progenitor and Stem Cells Circulate by Surfing on Intracellular Ca ²⁺ Waves: A Novel Target for Cell-based Therapy and Anti-cancer Treatment?. <i>Current Signal Transduction Therapy</i> , 2012, 7, 161-176.	0.3	41
120	A3669G polymorphism of glucocorticoid receptor is a susceptibility allele for primary myelofibrosis and contributes to phenotypic diversity and blast transformation. <i>Blood</i> , 2012, 120, 3112-3117.	0.6	33
121	Evidence that Prefibrotic Myelofibrosis Is Aligned along a Clinical and Biological Continuum Featuring Primary Myelofibrosis. <i>PLoS ONE</i> , 2012, 7, e35631.	1.1	85
122	Store-Operated Ca ²⁺ Entry Is Remodelled and Controls In Vitro Angiogenesis in Endothelial Progenitor Cells Isolated from Tumoral Patients. <i>PLoS ONE</i> , 2012, 7, e42541.	1.1	121
123	The strange case of the lost <i>NRAS</i> mutation in a child with juvenile myelomonocytic leukemia. <i>Pediatric Blood and Cancer</i> , 2012, 59, 580-582.	0.8	2
124	JAK2 46/1 haplotype predisposes to splanchnic vein thrombosis-associated BCR-ABL negative classic myeloproliferative neoplasms. <i>Leukemia Research</i> , 2012, 36, e7-e9.	0.4	17
125	Management of Myeloproliferative Neoplasms: From Academic Guidelines to Clinical Practice. <i>Current Hematologic Malignancy Reports</i> , 2012, 7, 50-56.	1.2	19
126	Regulatory Mrna/Microrna Networks in CD34+ Cells From Primary Myelofibrosis.. <i>Blood</i> , 2012, 120, 2854-2854.	0.6	0

#	ARTICLE	IF	CITATIONS
127	JAK2 V617F Genotype Is a Strong Determinant of Blast Transformation in Primary Myelofibrosis.. Blood, 2012, 120, 2829-2829.	0.6	0
128	Evaluation of the bioactive and total transforming growth factor β 1 levels in primary myelofibrosis. Cytokine, 2011, 53, 100-106.	1.4	29
129	High-dose erythropoietin in patients with acute myocardial infarction: A pilot, randomised, placebo-controlled study. International Journal of Cardiology, 2011, 147, 124-131.	0.8	76
130	In Vitro Megakaryocyte Differentiation and Proplatelet Formation in Ph-Negative Classical Myeloproliferative Neoplasms: Distinct Patterns in the Different Clinical Phenotypes. PLoS ONE, 2011, 6, e21015.	1.1	48
131	Splenectomy produces a rapid but transient decrease of the frequency of circulating CD34 ⁺ haematopoietic progenitor cells in primary myelofibrosis. British Journal of Haematology, 2011, 152, 665-667.	1.2	3
132	Cell fusion in tumor progression: the isolation of cell fusion products by physical methods. Cancer Cell International, 2011, 11, 32.	1.8	12
133	Vascular Endothelial Growth Factor Stimulates Endothelial Colony Forming Cells Proliferation and Tubulogenesis by Inducing Oscillations in Intracellular Ca ²⁺ Concentration. Stem Cells, 2011, 29, 1898-1907.	1.4	140
134	Therapeutic approaches in myelofibrosis. Expert Opinion on Pharmacotherapy, 2011, 12, 1597-1611.	0.9	25
135	Prefibrotic Myelofibrosis (PreMF) Belongs to a Continuum of Epidemiological, Clinical and Histological Characteristics Featuring Primary Myelofibrosis (PMF). Blood, 2011, 118, 1743-1743.	0.6	1
136	High Frequency of Endothelial Colony Forming Cells Marks a Non-Active Myeloproliferative Neoplasm with High Risk of Splanchnic Vein Thrombosis. PLoS ONE, 2010, 5, e15277.	1.1	30
137	Embryonic stem and haematopoietic progenitor cells resist to A β oligomer toxicity and maintain the differentiation potency in culture. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2010, 17, 137-145.	1.4	3
138	Store-Operated Ca ²⁺ Entry Is Expressed in Human Endothelial Progenitor Cells. Stem Cells and Development, 2010, 19, 1967-1981.	1.1	104
139	Prevalence and pathogenesis of anemia in inflammatory bowel disease. Influence of anti-tumor necrosis factor- α treatment. Haematologica, 2010, 95, 199-205.	1.7	140
140	From cancer patients to cancer survivors: The issue of Cardioncology – A biological perspective. European Journal of Cancer, 2010, 46, 697-702.	1.3	8
141	In Vitro Expanded MSCs From Patients with Myeloproliferative Neoplasms at Late Passages Show Recurrent Cytogenetic Abnormalities. Blood, 2010, 116, 4101-4101.	0.6	1
142	Study of Megakaryopoiesis and Proplatelet Formation In Myeloproliferative Disorders. Blood, 2010, 116, 3075-3075.	0.6	0
143	Novel strategies for patients with chronic myeloproliferative disorders. Current Opinion in Hematology, 2009, 16, 129-134.	1.2	11
144	Circulating Endothelial Progenitor Cells in Preterm Infants with Bronchopulmonary Dysplasia. American Journal of Respiratory and Critical Care Medicine, 2009, 180, 540-546.	2.5	137

#	ARTICLE	IF	CITATIONS
145	Rapid and large increase of the frequency of circulating endothelial colony-forming cells (ECFCs) generating late outgrowth endothelial cells in patients with acute myocardial infarction. <i>Experimental Hematology</i> , 2009, 37, 8-9.	0.2	54
146	Germ-line mutation of the <i>NRAS</i> gene may be responsible for the development of juvenile myelomonocytic leukaemia. <i>British Journal of Haematology</i> , 2009, 147, 706-709.	1.2	46
147	The Early- and Intermediate-Term Toxicity to Primitive Hematopoietic Progenitor Cells of Three Chemotherapy Regimens for Advanced Hodgkin Lymphoma. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, 425-429.	1.4	4
148	Endothelial colony-forming cells from patients with chronic myeloproliferative disorders lack the disease-specific molecular clonality marker. <i>Blood</i> , 2009, 114, 3127-3130.	0.6	79
149	Hypermethylation of <i>CXCR4</i> Promoter in CD34+ Cells from Patients with Primary Myelofibrosis. <i>Stem Cells</i> , 2008, 26, 1920-1930.	1.4	91
150	Immunophenotypic, cytogenetic and functional characterization of circulating endothelial cells in myelodysplastic syndromes. <i>Leukemia</i> , 2008, 22, 530-537.	3.3	45
151	Biological and clinical relevance of matrix metalloproteinases 2 and 9 in acute myeloid leukaemias and myelodysplastic syndromes. <i>European Journal of Haematology</i> , 2008, 80, 216-226.	1.1	39
152	A High Sensitivity Detection Technique Reveals JAK2-V617F Mutation in Additional 20% of Patients with Essential Thrombocytemia, but Not in Patients with Primary Myelofibrosis, Considered Negative with a Conventional ASO-PCR. <i>Blood</i> , 2008, 112, 2801-2801.	0.6	0
153	Vascular endothelial growth factor promoted endothelial progenitor cell mobilization into the peripheral blood of a patient with POEMS syndrome. <i>Haematologica</i> , 2007, 92, 1291-1292.	1.7	19
154	Early haemoglobin-independent increase of plasma erythropoietin levels in patients with acute myocardial infarction. <i>European Heart Journal</i> , 2007, 28, 1805-1813.	1.0	55
155	Congenital amegakaryocytic thrombocytopenia: clinical and biological consequences of five novel mutations. <i>Haematologica</i> , 2007, 92, 1186-1193.	1.7	53
156	JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. <i>Blood</i> , 2007, 110, 4030-4036.	0.6	233
157	The expression of CXCR4 is down-regulated on the CD34+ cells of patients with myelofibrosis with myeloid metaplasia. <i>Blood Cells, Molecules, and Diseases</i> , 2007, 38, 280-286.	0.6	60
158	FIP1L1-PDGFR α in chronic eosinophilic leukemia and BCR-ABL1 in chronic myeloid leukemia affect different leukemic cells. <i>Leukemia</i> , 2007, 21, 397-402.	3.3	21
159	Anaemia characterises patients with myelofibrosis harbouring MplW515L/Kmutation. <i>British Journal of Haematology</i> , 2007, 137, 244-247.	1.2	153
160	Modulated Expression of BCL-xL and GATA-1 Genes Is a Common Feature in Myeloproliferative Disorders (MPD) Both in JAK2-V617F Positive and Negative Patients. <i>Blood</i> , 2007, 110, 1533-1533.	0.6	0
161	Reduced CD26 Dipeptidylpeptidase IV Membrane Expression and Activity of CD34+ Cells from Patients with Myelofibrosis with Myeloid Metaplasia. <i>Blood</i> , 2006, 108, 3617-3617.	0.6	0
162	Increased circulating hematopoietic and endothelial progenitor cells in the early phase of acute myocardial infarction. <i>Blood</i> , 2005, 105, 199-206.	0.6	438

#	ARTICLE	IF	CITATIONS
163	Overexpression of the Doppel protein in acute myeloid leukaemias and myelodysplastic syndromes. <i>British Journal of Haematology</i> , 2005, 128, 877-884.	1.2	10
164	Circulating CD34+, CD133+, and Vascular Endothelial Growth Factor Receptor 2â€“Positive Endothelial Progenitor Cells in Myelofibrosis With Myeloid Metaplasia. <i>Journal of Clinical Oncology</i> , 2005, 23, 5688-5695.	0.8	81
165	Reduced Expression of CXCR4 on Circulating CD34+ Cells Is Associated with Hematopoietic Progenitor Cells (HPC) Mobilization in Patients with Myelofibrosis with Myeloid Metaplasia (MMM).. <i>Blood</i> , 2005, 106, 258-258.	0.6	3
166	SDF-1/CXCR4 Interactions in Idiopathic Myelofibrosis.. <i>Blood</i> , 2005, 106, 3504-3504.	0.6	0
167	Effects of the R216Q mutation of GATA-1 on erythropoiesis and megakaryocytopoiesis. <i>Thrombosis and Haemostasis</i> , 2004, 91, 129-140.	1.8	105
168	Spleen neoangiogenesis in patients with myelofibrosis with myeloid metaplasia. <i>British Journal of Haematology</i> , 2004, 124, 618-625.	1.2	43
169	Evaluation of Cytokines Mobilizing Hematopoietic Progenitor Cells in Patients with Myelofibrosis with Myeloid Metaplasia (MMM).. <i>Blood</i> , 2004, 104, 2434-2434.	0.6	0
170	1981 Increased proportion of circulating progenitor cells in the early phase of acute myocardial infarction. <i>European Heart Journal</i> , 2003, 24, 366.	1.0	1
171	Glycosylphosphatidylinositol-linked proteins are required for maintenance of a normal peripheral lymphoid compartment but not for lymphocyte development. <i>European Journal of Immunology</i> , 2002, 32, 2607-2616.	1.6	16
172	Maternally transmitted severe glucose 6-phosphate dehydrogenase deficiency is an embryonic lethal. <i>EMBO Journal</i> , 2002, 21, 4229-4239.	3.5	123
173	Murine Models of Paroxysmal Nocturnal Hemoglobinuria. <i>Annals of the New York Academy of Sciences</i> , 2002, 963, 290-296.	1.8	13
174	Diagnostic and clinical relevance of the number of circulating CD34+ cells in myelofibrosis with myeloid metaplasia. <i>Blood</i> , 2001, 98, 3249-3255.	0.6	197
175	Ex vivo priming for long-term maintenance of antileukemia human cytotoxic T cells suggests a general procedure for adoptive immunotherapy. <i>Blood</i> , 2001, 98, 3359-3366.	0.6	55
176	Interferon-Î± protects Philadelphia-negative progenitors from exhaustion in chronic myeloid leukemia patients with cytogenetic response. <i>The Hematology Journal</i> , 2001, 2, 26-32.	2.0	2
177	[30] Inhibition of c-ABL expression in hematopoietic progenitor cells using antisense oligodeoxynucleotides. <i>Methods in Enzymology</i> , 2000, 314, 429-440.	0.4	0
178	Cell cycle distribution of cord blood-derived haematopoietic progenitor cells and their recruitment into the S-phase of the cell cycle. <i>British Journal of Haematology</i> , 2000, 108, 621-628.	1.2	11
179	Autografting with Ph-negative progenitors in patients at diagnosis of chronic myeloid leukemia induces a prolonged prevalence of Ph-negative hemopoiesis. <i>Experimental Hematology</i> , 2000, 28, 210-215.	0.2	5
180	Stable in vivo expression of glucose-6-phosphate dehydrogenase (G6PD) and rescue of G6PD deficiency in stem cells by gene transfer. <i>Blood</i> , 2000, 96, 4111-4117.	0.6	25

#	ARTICLE	IF	CITATIONS
181	Familial-skewed X-chromosome inactivation as a predisposing factor for late-onset X-linked sideroblastic anemia in carrier females. <i>Blood</i> , 2000, 96, 4363-4365.	0.6	86
182	Familial-skewed X-chromosome inactivation as a predisposing factor for late-onset X-linked sideroblastic anemia in carrier females. <i>Blood</i> , 2000, 96, 4363-4365.	0.6	1
183	Stable in vivo expression of glucose-6-phosphate dehydrogenase (G6PD) and rescue of G6PD deficiency in stem cells by gene transfer. <i>Blood</i> , 2000, 96, 4111-4117.	0.6	1
184	Increased Sensitivity to Complement and a Decreased Red Blood Cell Life Span in Mice Mosaic for a Nonfunctional Piga Gene. <i>Blood</i> , 1999, 94, 2945-2954.	0.6	100
185	X inactivation and somatic cell selection rescue female mice carrying a Piga-null mutation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1999, 96, 7479-7483.	3.3	61
186	Normal primitive haemopoietic progenitors are more frequent than their leukaemic counterpart in newly diagnosed patients with chronic myeloid leukaemia but rapidly decline with time. <i>British Journal of Haematology</i> , 1999, 104, 538-545.	1.2	11
187	Increased Sensitivity to Complement and a Decreased Red Blood Cell Life Span in Mice Mosaic for a Nonfunctional Piga Gene. <i>Blood</i> , 1999, 94, 2945-2954.	0.6	4
188	Unbalanced X-chromosome inactivation in haemopoietic cells from normal women. <i>British Journal of Haematology</i> , 1998, 102, 996-1003.	1.2	81
189	Murine embryonic stem cells without pig-a gene activity are competent for hematopoiesis with the PNH phenotype but not for clonal expansion.. <i>Journal of Clinical Investigation</i> , 1997, 100, 1028-1036.	3.9	122
190	Defective iron supply for erythropoiesis and adequate endogenous erythropoietin production in the anemia associated with systemic-onset juvenile chronic arthritis. <i>Blood</i> , 1996, 87, 4824-4830.	0.6	169
191	TREATMENT WITH RETINOIDS AND HAEMOPOIETIC GROWTH FACTORS IN MYELODYSPLASTIC SYNDROMES. <i>British Journal of Haematology</i> , 1995, 91, 773-774.	1.2	0
192	Juvenile chronic myelogenous leukemia: In vitro characterization before and after allogeneic bone marrow transplantation. <i>Medical and Pediatric Oncology</i> , 1995, 24, 166-170.	1.0	2
193	Cell kinetics of CD34-positive hematopoietic cells following chemotherapy plus colony-stimulating factors in advanced breast cancer. <i>International Journal of Cancer</i> , 1995, 63, 646-651.	2.3	9
194	The molecular basis of paroxysmal nocturnal hemoglobinuria. <i>Blood</i> , 1995, 86, 3277-3286.	0.6	222
195	Oligodeoxynucleotides antisense to c-abl specifically inhibit entry into S-phase of CD34+ hematopoietic cells and their differentiation to granulocyte-macrophage progenitors. <i>Blood</i> , 1995, 86, 3387-3393.	0.6	33
196	THE USE OF PERIPHERAL-BLOOD HEMATOPOIETIC PROGENITORS MOBILIZED WITH STANDARD-DOSE CHEMOTHERAPY PLUS GRANULOCYTE-COLONY-STIMULATING FACTOR TO SUPPORT MULTICYCLIC DOSE-INTENSIVE CHEMOTHERAPY FOR ADVANCED BREAST-CANCER. <i>Oncology Reports</i> , 1995, 2, 1075-8.	1.2	1
197	Oligodeoxynucleotides antisense to c-abl specifically inhibit entry into S-phase of CD34+ hematopoietic cells and their differentiation to granulocyte-macrophage progenitors. <i>Blood</i> , 1995, 86, 3387-93.	0.6	12
198	Regulation of erythropoietin production in a case of congenital erythropoietin-dependent pure erythrocytosis. <i>American Journal of Hematology</i> , 1994, 46, 348-353.	2.0	4

#	ARTICLE	IF	CITATIONS
199	Intravenous iron therapy for severe anaemia in systemic-onset juvenile chronic arthritis. <i>Lancet</i> , The, 1994, 344, 1052-1054.	6.3	63
200	Restoration of normal polyclonal haemopoiesis in patients with chronic myeloid leukaemia autografted with Ph ⁺ negative peripheral stem cells. <i>British Journal of Haematology</i> , 1994, 87, 867-870.	1.2	28
201	Giant cell formation in Hodgkin's disease. <i>Research in Immunology</i> , 1994, 145, 499-515.	0.9	10
202	Toxic Epidermal Necrolysis Following <i>Yersinia enterocolitica</i> Infection. <i>International Journal of Dermatology</i> , 1993, 32, 75-75.	0.5	4
203	CD45 ⁺ FMS EXPRESSION IN B CELLS AND RESPONSE TO GM-CSF. <i>British Journal of Haematology</i> , 1993, 84, 755-756.	1.2	1
204	Acquired cyclic thrombocytopenia and thrombocytosis with periodic defect of platelet function. <i>British Journal of Haematology</i> , 1993, 85, 718-722.	1.2	20
205	Analysis of Factors Predicting Response to Recombinant Human Erythropoietin in Nonrenal Anaemia. <i>Leukemia and Lymphoma</i> , 1992, 7, 100-100.	0.6	0
206	Subcutaneous erythropoietin for treatment of refractory anemia in hematologic disorders. Results of a phase I/II clinical trial [see comments]. <i>Blood</i> , 1992, 79, 29-37.	0.6	118
207	An atypical myeloproliferative disorder with high thrombotic risk and slow disease progression. <i>Cancer</i> , 1992, 70, 1647-1649.	2.0	0
208	Subcutaneous erythropoietin for treatment of refractory anemia in hematologic disorders. Results of a phase I/II clinical trial [see comments]. <i>Blood</i> , 1992, 79, 29-37.	0.6	35
209	c-abl function in normal and chronic myelogenous leukemia hematopoiesis: in vitro studies with antisense oligomers. <i>Leukemia</i> , 1992, 6, 1-7.	3.3	103
210	An atypical myeloproliferative disorder with high thrombotic risk and slow disease progression. <i>Cancer</i> , 1991, 68, 2310-2318.	2.0	33
211	Immunocytochemical detection of ferritin in human bone marrow and peripheral blood cells using monoclonal antibodies specific for the H and L subunit. <i>British Journal of Haematology</i> , 1990, 76, 427-432.	1.2	27